Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang H M, Nolan J
Department of Family and Preventive Medicine, University of California, San Diego, School of Medicine, La Jolla 92093-0607, USA.
J Reprod Med. 1999 Dec;44(12):1012-20.
To compare the effects of two doses of conjugated equine estrogen (CEE) and two of esterified estrogen plus methyltestosterone (E + A) in surgically menopausal women.
A two-year, parallel-group, double-blind study of 311 women who were randomly assigned to one of four regimens: (1) CEE, 0.625 mg/d; (2) CEE, 1.25 mg/d; (3) esterified estrogens, 0.625 mg, + methyltestosterone, 1.25 mg/d; or (4) esterified estrogens, 1.25, + methyltestosterone, 2.5 mg/d. Study parameters were symptoms, lipids, bone mineral density, side effects and safety.
All treatments prevented loss of bone in the spine and hip. The higher E + A dose increased spine and hip BMD more than other treatments (P < .002). All treatments improved menopausal symptoms, with non-significantly greater improvements in well-being and sexual interest in the E + A groups. Similar and significant decreases in low-density lipoprotein were observed in all groups, but high-density lipoprotein and triglycerides were increased only in the unopposed estrogen groups (P < .05). Hirsutism was uncommon and similar in all groups at two years. Discontinuation rates and reasons for withdrawal from the study were similar in both groups. No clinically significant side effects or laboratory test abnormalities were seen.
As compared to estrogen alone, E + A significantly improved BMD and was well tolerated in surgically menopausal women.
比较两种剂量的结合马雌激素(CEE)和两种剂量的酯化雌激素加甲基睾酮(E + A)对手术绝经后女性的影响。
一项为期两年的平行组双盲研究,311名女性被随机分配到四种治疗方案之一:(1)CEE,0.625毫克/天;(2)CEE,1.25毫克/天;(3)酯化雌激素,0.625毫克,加甲基睾酮,1.25毫克/天;或(4)酯化雌激素,1.25毫克,加甲基睾酮,2.5毫克/天。研究参数包括症状、血脂、骨矿物质密度、副作用和安全性。
所有治疗均预防了脊柱和髋部的骨质流失。较高剂量的E + A比其他治疗更能增加脊柱和髋部的骨密度(P <.002)。所有治疗均改善了绝经症状,E + A组在幸福感和性兴趣方面的改善虽无显著差异,但有所增加。所有组的低密度脂蛋白均有相似且显著的降低,但高密度脂蛋白和甘油三酯仅在单纯雌激素组中升高(P <.05)。多毛症在两年时在所有组中均不常见且相似。两组的停药率和退出研究的原因相似。未观察到具有临床意义的副作用或实验室检查异常。
与单独使用雌激素相比,E + A显著改善了骨密度,并且在手术绝经后女性中耐受性良好。